DIMERx to Present Data Showcasing Non-Addictive Opioid Dimer DMX-101 for Chronic Pain at PAINWeek 2023

Potential to treat chronic pain without risks associated with traditional opioids by exclusively targeting peripheral pain receptors

SAN FRANCISCO--()--DIMERx, Inc., a mid-stage biopharmaceutical company, today announced that it will present data at PAINWeek 2023, the 17th Annual National Conference on Pain for Healthcare Providers, being held September 5-8, 2023, in Las Vegas, Nevada. Nikhilesh N. Singh, Ph.D., inventor and Chief Executive Officer of DIMERx, will present the evidence of safety, efficacy and target engagement to support development of DMX-101 as a non-addictive opioid for treatment of chronic pain.

DMX-101 has been designed to exclusively engage the peripheral μ and κ opioid receptors, which account for 60-80% of all opioid receptors in the body, at the source to control pain without penetrating the brain, and consequently without producing central nervous system-related side effects such as drowsiness, euphoria, and addiction.

“I am delighted to have the opportunity to present our data to academia and a peer group of specialists and practitioners focused on pain management,” stated Dr. Singh. “DMX-101 is proving to be a transformative molecule which could potentially manage chronic pain and also various gastrointestinal functional disorders.”

Details of the presentation are below:

Title: Novel, Non-Addictive Opioid Dimer DMX-101 Targets Peripheral Opioid Receptors for Treatment of Chronic Pain without Risks Associated with Traditional Opioids

Date: Thursday, September 7

Time: 5:30-6:30 p.m. PDT

Location: The Cosmopolitan of Las Vegas, Belmont Ballroom

General poster viewing sessions: September 6, 6:00-8:00 p.m.; September 7, 10:30 a.m.-6:30 p.m.; September 8, 10:30 a.m.-1:30 p.m. PDT.

Following presentation at the conference, the poster will be available at www.dimerx.com.

About DIMERx, Inc.

DIMERx is a clinical-stage biopharmaceutical company focused on the development of innovative and de-risked first-in-class dimer therapeutics. Leveraging its proprietary dimer platform technology engineered by founder Nikhilesh Singh, Ph.D., DIMERx is advancing DMX-101 and a pipeline of additional dimer conjugates. DIMERx is currently raising Series A financing to see DMX-101 through clinical proof of concept for chronic pain and advance at least one additional dimer to the point of filing an Investigational New Drug submission with the FDA. DMX-101 is also Phase 2b/3a ready for chronic treatment of IBS-D in patients with and without gallbladder.

Forward-Looking Statements

This press release contains “forward-looking statements,” which reflect our current views and expectations with respect to future outcomes or events. When used in this press release, the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Because these statements are based on current estimates and assumptions, they are inherently subject to risks that could cause the actual outcomes to differ materially from what we currently expect. These forward-looking statements are subject to numerous risks and uncertainties, including, among others, the facts that we are substantially dependent on our ability to successfully develop and commercialize our products; the commercial adoption of our products and any other product candidates we develop will depend on the degree of their market acceptance; we have only limited assets and will need to raise additional capital before we can expect to generate revenue or become profitable; and we have never generated any revenue and may never be profitable. Forward-looking statements in this presentation apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.


Investor Relations

Release Summary

DIMERx will present data on DMX-101, a non-addictive opioid with potential to treat chronic pain without risks associated with traditional opioids.


Investor Relations